PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-26.68%
Both companies show declining cash positions (-26.68% vs CRVO's -26.67%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-26.68%
Similar yoy growth to CRVO's -26.67%. Walter Schloss would note comparable liquidity expansions. Examine capital usage strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-45.50%
Higher Other Current Assets Growth compared to CRVO's zero value, indicating worse performance.
-27.05%
Similar yoy growth to CRVO's -28.60%. Walter Schloss notes comparable short-term expansions. Investigate quality of these assets.
-7.44%
Similar yoy growth to CRVO's -6.84%. Walter Schloss sees parallel capital spending strategies. Check utilization rates.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both CRVO and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
12.75%
Less than half of CRVO's -0.17%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-5.69%
≥ 1.5x CRVO's -0.43%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-25.21%
≥ 1.5x CRVO's -14.43%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
9.15%
Above 1.5x CRVO's 2.73%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-74.86%
Higher Short-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-9.15%
Both CRVO and the company show zero Deferred Revenue (Current) Growth.
No Data
No Data available this quarter, please select a different quarter.
7.01%
Less than half of CRVO's 16.82%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.56%
50-75% of CRVO's -14.55%. Bruce Berkowitz notes a smaller yoy liability buildup than competitor.
No Data
No Data available this quarter, please select a different quarter.
4.31%
Less than half of CRVO's -2.66%. David Dodd sees far fewer liability expansions relative to competitor.
1.65%
Higher Common Stock (Book Value) Growth compared to CRVO's zero value, indicating worse performance.
-3.34%
Similar yoy to CRVO's -3.29%. Walter Schloss sees parallel earnings retention vs. competitor.
-6.51%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-36.72%
≥ 1.5x CRVO's -16.43%. David Dodd sees stronger capital base growth than competitor.
-25.21%
≥ 1.5x CRVO's -14.43%. David Dodd sees faster overall balance sheet growth than competitor.
-100.00%
Both CRVO and the company show zero Total Investments Growth.
-11.75%
Above 1.5x CRVO's -7.58%. Michael Burry sees a major jump. Investigate leverage rationale.
27.85%
Similar yoy changes to CRVO's 27.36%. Walter Schloss sees parallel net leverage strategies.